AGORACOM Small Cap TV - December 24, 2008
23
Dec
Stock Market Technical Analysis December 23, 2008
Posted by: GCM / Category: Daily Technical AnalysisStock Market Technical Analysis December 23, 2008
23
Dec
Stock Indexes Review for December 23, 2008
Posted by: GCM / Category: Daily Stock Indexes ReviewStock Indexes Review for December 23, 2008
Intra Day Analysis 12-23-08
DOR BioPharma, Inc., a biopharmaceutical company, engages in the research and development of oral therapeutic products intended for areas of unmet medical needs and biodefense vaccines in the United States and internationally. The company operates through two segments, BioTherapeutics and BioDefense. The BioTherapeutics segment develops orBec, an orally administered corticosteroid, which exerts a potent and local anti-inflammatory effect in the mucosal tissue of the gastrointestinal tract; Oraprine, an oral suspension of azathioprine; and LPE and PLP systems for delivery of water-insoluble drugs. The BioDefense segment offers RiVax, ricin toxin vaccine, a heat stable toxin that is isolated and purified from the bean of the castor plant; and BT-VACC, the Botulinum toxin, a poisonous natural substance, which causes acute, symmetric, and descending flaccid paralysis due to its action on peripheral cholinergic nerves. It has a collaborative agreement with IDIS Limited for the supply and distribution of investigational drug orBec for the treatment of gastrointestinal graft-versus-host disease in the European Union. DOR BioPharma, Inc. was founded in 1987 and is headquartered in Ewing, New Jersey.
